EUCTR2009-011464-11-DE进行中（未招募）不适用
EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
Vertex Pharamceuticals, Inc.0 个研究点目标入组 400 人开始时间: 2009年7月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject must:
- •1. Have received at least 1 dose of telaprevir-based treatment in 1 of the following clinical studies: VX05-950-104, VX05-950-104EU, VX06-950-106, VX06-950-107, VX07-950-108, VX08-950-111, or VX-950-TiDP24-C216.
- •2. Have baseline HCV viral sequencing data available from previous telaprevir study.
- •3. Be able and willing to give informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The subject must not:
- •1. Be currently participating in the antiviral follow-up period of an ongoing telaprevir trial. (Note: Subjects who have completed the required antiviral follow-up period but are still participating in the collection of patient reported outcomes data for their previous telaprevir study may be eligible.)
- •2. For subjects participating in ongoing studies at the time of enrollment, have more than 90 elapsed days between the database lock or unblinding in the previous telaprevir study and Day 1 in this study.
研究者
相似试验
进行中（未招募）
1 期
EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical StudiesHepatitis C virus infectionMedDRA version: 12.0Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)EUCTR2009-011464-11-FRVertex Pharamceuticals, Inc.408
已完成
不适用
Virology Follow up Study in Subjects Previously Treated With TelaprevirHepatitis CNCT00916474Vertex Pharmaceuticals Incorporated408
进行中（未招募）
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-001448-90-FRAnaptysBio Inc.45
进行中（未招募）
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-001448-90-DEAnaptysBio Inc.45
进行中（未招募）
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-001448-90-ESAnaptysBio Inc.45